v3.26.1
Note 14 - Strategic Alliances (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 40 Months Ended 54 Months Ended
Mar. 16, 2025
Mar. 08, 2023
Sep. 14, 2021
Jun. 18, 2021
May 05, 2020
Feb. 25, 2010
Sep. 30, 2024
Jun. 30, 2026
Jun. 30, 2025
Mar. 31, 2023
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2026
Dec. 31, 2025
Dec. 30, 2025
Oct. 28, 2025
Jan. 07, 2025
Oct. 01, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Revenues               $ 163,580 $ 156,807   $ 287,777 $ 306,759              
Transfer of Intellectual Property and Other [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Revenues               46,090 $ 14,963   60,058 27,229              
Corporate Joint Venture [Member] | LeaderMed Joint Venture [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Revenues     $ 1,000                                
Subsidiary, Ownership Percentage, Parent     47.00%                                
LeaderMed [Member] | Corporate Joint Venture [Member] | LeaderMed Joint Venture [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Payments to Acquire Interest in Joint Venture     $ 11,000                                
Subsidiary, Ownership Percentage, Noncontrolling Owner     53.00%                                
Collaboration and License Agreement With Entera [Member] | Entera Ordinary Shares [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Investment Owned, Shares Purchased (in shares) 3,685,226                                    
Payments to Acquire Investments, Total $ 8,000                                    
Shares Purchased, Price Per Share (in dollars per share) $ 2.17                                    
Payments to Acquire Investments $ 8,000                                    
Collaboration and License Agreement With Entera [Member] | Opko [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Ownership, Percentage 60.00%                                    
Collaboration and License Agreement With Entera [Member] | Entera [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Ownership, Percentage 40.00%                                    
Collaboration and License Agreement With Entera [Member] | Entera [Member] | Entera Discontinuing Funding [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Ownership, Percentage 15.00%                                    
BARDA Agreement [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Collaborative Arrangement, Supplement for Advance of Development             $ 26,900                        
Revenues             $ 24,100       9,000 $ 13,500              
Collaborative Arrangement, Value                             $ 103,500 $ 110,000      
Collaborative Arrangement, Value, Including Milestones                             198,500 $ 205,000      
Aggregate Transaction Price Allocated to Remaining Performance Obligations, Excluding Unexercised Contract Options, Amount                     40,900                
Merck Agreement [Member] | Merck Sharp & Dohme LLC [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Revenues   $ 50,000                                  
Collaborative Arrangement, Development Milestone Payment   $ 860,000                               $ 12,500  
Collaborative Arrangement, Development Costs                         $ 27,100            
Development and License Agreement [Member] | NICOYA Macau Limited [Member] | EirGen [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Revenues       $ 5,000           $ 2,500                  
Collaborative Agreement, Delayed Payment       $ 5,000                              
Collaborative Agreement, Delayed Payment Received, Cumulative                   $ 2,500                  
Collaborative Arrangement, Period Following First Commercial Sale (Year)       10 years                              
Development and License Agreement [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] | EirGen [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Collaborative Arrangement, Maximum Regulatory Milestone Payments         $ 15,000                            
Collaborative Arrangement, Sales Milestone Payment         200,000                            
Collaborative Agreement, Option, Sales Milestone Payments         555,000                            
Development and License Agreement [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] | EirGen [Member] | First Marketing Approval of Rayaldee in Europe [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Revenues         3,000                            
Development and License Agreement [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] | EirGen [Member] | Germany Price Approval by Local Sick Fund Association [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Revenues         $ 7,000                            
Regeneron Collaboration Agreement [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Collaborative Arrangement, Upfront Payments                                 $ 7,000    
Regeneron Collaboration Agreement [Member] | Minimum [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Collaborative Arrangement, Aggregate Milestone Payments                                 200,000    
Overall value of the collaboration                                 $ 1,000,000    
Pfizer Agreement [Member] | Pfizer Inc. [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Revenues                           $ 175,000          
Collaborative Arrangement, Maximum Regulatory Milestone Payments                                     $ 275,000
Revenue, Remaining Performance Obligation, Amount                                     295,000
Contract with Customer, Liability               $ 0     0   $ 0 $ 0 $ 0        
Pfizer Agreement [Member] | Pfizer Inc. [Member] | Minimum [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Collaborative Agreements, Each Milestone Payment                                     20,000
Pfizer Agreement [Member] | Pfizer Inc. [Member] | Maximum [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Collaborative Agreements, Each Milestone Payment                                     $ 90,000
Worldwide License Agreement With Eli Lilly [Member] | Eli Lilly and Company [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Royalty percent           3.00%                          
Revenue                     $ 4,600                
Amended and Restated Entera Collaboration and License Agreement [Member]                                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                      
Ownership, Percentage 50.00%